⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure 9 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Gillian Vandekerkhove Andrew J. Murtha David C. Müller Maria Stephenson Kimia Rostin Aslı D. Munzur Carlos Vasquez-Rios Jussi Nikkola Joonatan Sipola Matti Annala Cameron Herberts Emily Fung Jaskirat Atwal Sadeem Al-Subaie Karan Parekh Cecily Q. Bernales Gráinne Donnellan Daygen L. Finch Krista Noonan Jenny J. Ko Güliz Özgün Lucia Nappi Christian Kollmannsberger Jean‐Michel Lavoie Sunil Parimi Tilman Todenhöfer Piet Ost Gang Wang Peter C. Black Corinne Maurice‐Dror Kim N.Bernhard J. Eigl Alexander W. Wyatt

View Full Paper

Ask AI

Bookmark

Share

Key Points

HER2 variance in tumor tissues is significant for understanding metastatic urothelial cancer.
The analysis indicates variability in HER2 immunohistochemistry across different tumor samples.
Observational analysis examines ctDNA and tissue alterations in patients with metastatic urothelial cancer.
Understanding HER2 alterations may highlight therapeutic targets for these cancer patients.

Implication

Observational analysis reveals HER2 variance in tumor tissues of metastatic urothelial cancer, implying implications for targeted therapies.

Abstract

Supplementary Figure 9. Variance in HER2 IHC across urothelial cancer (UC) tumor tissue.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vandekerkhove et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02b0d https://doi.org/10.1158/1078-0432.30029633

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
2Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
3Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
4Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
5Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025